News In blink-and-miss-it moment, Harris vows to expand OOP cap The US Presidential debate barely mentioned pharma topics, but Harris did have one notable sound bite toward the very end of the night.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.